|Description||ONO-4057 is a leukotriene B4 receptor antagonist originated by Ono Pharmaceutical. ONO-4057 is an Immunologic Factor and Immunosuppressive Agent. Clinical trials for the treatment of Behcet's syndrome, Gastritis and Ulcerative colitis was discontinued.|
|Synonyms||Ono-LB-457; (E)-5-(2-(2-carboxyethyl)-3-((6-(4-methoxyphenyl)hex-5-en-1-yl)oxy)phenoxy)pentanoic acid|
|Solubility||Soluble in DMSO|
|Application||Behcet's syndrome; Gastritis; Ulcerative colitis|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Ono Pharmaceutical|
Iralukast is a Leukotriene D4 receptor antagonist originated by Novartis as a a structural analogue of LTD4. It is applicated for the treatment of asthma and in...
ZM-230487, a quinolin derivative, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene D4 receptor antagonist. It was once studied in anti-inf...
This active molecular is a competitive leukotriene B4 receptor antagonist and IC50 value is about 100 nM. LY 255283 is selective for the BLT2 receptor, since IC...
This active molecular is a selective LTD4 antagonist. CP-85958 may become a clinical candidates for the treatment of asthma in the future.
Acebilustat, formerly known as ZK322, is an oral anti-inflammatory designed to reduce the production of leukotriene B4 (LTB4),.
LY 213024 is a potent leukotriene B4 receptor antagonist. Agents which block the production of the leukotrienes have shown reduction of infarct size in animal m...
LY 203647 is a a leukotriene D4 and E4 receptor antagonist with a tetrazole nucleus structure originated by Eli Lilly. No development for treatment of Ischaemic...
KP496, a novel dual antagonist of cysLT receptor and TP, is currently in clinical development as a dry powder inhaler. KP496 inhibited epithelial hypertrophy an...
ONO-4057 is a leukotriene B4 receptor antagonist originated by Ono Pharmaceutical. ONO-4057 is an Immunologic Factor and Immunosuppressive Agent. Clinical trial...
U66858, also known as Bunaprolast, is a hydroquinone inhibitor of leukotriene synthesis, which inhibits LTB4 production in human whole blood.
Ono-RS-347 is an SRS-A antagonist and a new leukotriene antagonists.
CP-195543 is a potent and selective leukotriene B4 antagonist developed as an oral treatment for for inflammatory diseases.
This active molecular is benzophenone dicarboxylic acid derivative which is a potent BLT1 receptor antagonist. It inhibits the binding of radiolabeled-LTB4 to i...
LY 210073, an oxoxanthene derivative, has been found to be a LTB4 receptor antagonist that could probably be effective against inflammation and rheumatic disord...
Cgp-35949 is an LTD4 antagonist which has phospholipase inhibitory activity. It represents a new approach to the treatment of asthma.
Atreleuton, a kind of urea compound, has been found to be a 5-lipoxygenase inhibitor as well as Leukotriene B4 receptor antagonist that could probably be useful...
Cinalukast is a selective Leukotriene D4 receptor antagonist originated by Roche and IC 50 value is 6.4 nM. Cinalukast inhibits the actions of Leukotriene D4 at...
This active molecular is an antihistamine, anticholinergic and mast cell stabilizer. Olopatadine blocks the action of endogenous histamine. It is used to treat ...
This active molecular is a leukotriene antagonist with the IC50 of 3 nM in human polymorphonuclear leukocytes. MK-886 also inhibits PPARα activation. Inhibition...
HAMI3379 is a cysteinyl leukotriene 2 (CysLT2) receptor antagonist. It can inhibit radioligand binding of LTD4 to CysLT2 and CysLT1 receptor cell lines with IC5...